Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ACC 25 Late-Breaking Discussion: The API-Cat Study
Author(s): Harriette Van Spall , Isabelle Mahé Added: 9 months ago
ACC 25 - The API-CAT Study shows reduced-dose apixaban is non-inferior to full-dose apixaban for extended anticoagulation in patients with active cancer who have completed 6 months of anticoagulant therapy for venous thromboembolism (VTE).Late-Breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Prof Isabelle Mahe (Paris Cite University, Paris, FR) to discuss the… View more

Anticoagulation

Vascular Disease and Surgery
ESC 25: The HI-PRO Trial
Author(s): Gregory Piazza Added: 4 months ago
ESC Congress 2025 - HI-PRO shows apixaban 2.5mg twice daily reduced the risk of symptomatic recurrent venous thromboembolism when compared to placebo at 12 months.Dr Gregory Piazza (Brigham and Women's Hospital, US) joins us to discuss findings from the HI-PRO trial, evaluating extended-duration low-intensity apixaban versus placebo for secondary prevention in high-risk patients with provoked… View more

Anticoagulation

Vascular Disease and Surgery
CardioNerds @AHA23: ARTESiA: Stroke Risk Reduction in Sub-Clinical AF: Apixaban vs Aspirin
Author(s): Naima Maqsood , Jeff Healey Added: 2 years ago
AHA 2023 — Dr Naima Maqsood, CardioNerds ambassador (Temple University Hospital, US) interviews investigator, Dr Jeff Healey (McMaster University, CA) to outline the findings from a phase 4 trial of apixaban to reduce thromboembolism in patients with subclinical atrial fibrillation (AF).ARTESiA (NCT01938248) aims to determine if apixaban in combination with aspirin can reduce the instance of… View more

Anticoagulation

Electrophysiology & Arrhythmia
ESC 24 Hot Line Discussion: The OCEANIC-AF Trial
Author(s): Manesh R Patel , Harriette Van Spall Added: 1 year ago
ESC Congress 2024 — OCEANIC-AF was halted early due to a lack of efficacy in 2023. Investigators shared details of the trial at ESC, comparing asundexian against apixaban in patients with atrial fibrillation at risk of stroke.Host Dr Harriette Van Spall (McMaster University, Hamilton, Canada) sits down with primary investigator Dr Manesh R Patel (Duke University Health System, USA) to discuss the… View more

Anticoagulation

Electrophysiology & Arrhythmia
EHRA 24: Insights from an ARTESiA Substudy
Author(s): William McIntyre Added: 1 year ago
EHRA 24 - Investigator, Dr William McIntyre (Population Health Research Institute, CA) joins us to discuss the findings from a substudy of ARTESiA (NCT01938248).ARTESiA was a randomized, parallel assignment clinical trial which aimed to assess if apixaban could reduce the risk of ischemic stroke and systemic embolism in patients with subclinical atrial fibrillation (AF) and additional risk… View more

Electrophysiology & Arrhythmia
Author(s): Apisara Lohachatinante , Nuttanun Kittikunkanyakit , Sayamon Sukkha , et al Added: 1 year ago

Anticoagulation
Factor XIa Inhibitors’ Future Position in AF
Author(s): Maki Komiyama , Moritake Iguchi , Hiromichi Wada , et al Added: 1 year ago

Anticoagulation
Anticoagulant Use in Older Adults
Author(s): Monika Bhandari , Akshyaya Pradhan , Pravesh Vishwakarma , et al Added: 11 months ago

Anticoagulation

Electrophysiology & Arrhythmia
Comparative Analysis of Direct Oral Anticoagulants in Atrial Fibrillation
Author(s): Ton Duy Mai , Tri Huynh Quang Ho , Sy Van Hoang , et al Added: 8 months ago

Anticoagulation

Electrophysiology & Arrhythmia
View from the Thoraxcenter: AHA 23 Late-breaking Science Wrap Up
Author(s): Nicolas M Van Mieghem , Joost Daemen Added: 2 years ago
What's hot at #AHA23?Join Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) as they review the late-breaking science data from AHA Scientific Sessions 2023.They interpret the evidence from five key trials, providing context, asking thought-provoking questions to translate the data into key take-home messages for practice and research.Trials Covered00:20 - DAPA… View more

Anticoagulation

Guidelines & Statements